We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

14 hedge funds and large institutions have $10.6M invested in Chemomab Therapeutics in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

523% more capital invested

Capital invested by funds: $1.71M → $10.6M (+$8.93M)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

0.01% more ownership

Funds ownership: 0.36% → 0.36% (+0.01%)

7% less funds holding

Funds holding: 15 → 14 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$146K
2
KPWS
Kestra Private Wealth Services
Texas
+$67.4K
3
BFM
Boothbay Fund Management
New York
+$30.7K
4
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$2.47K
5
Morgan Stanley
Morgan Stanley
New York
+$863

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$71K
2
Citadel Advisors
Citadel Advisors
Florida
-$53K
3
Osaic Holdings
Osaic Holdings
Arizona
-$1.32K
4
UBS Group
UBS Group
Switzerland
-$561
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$8.25M – – –
IC
2
Ikarian Capital
Texas
$1M +$146K +16,874 +27%
CAM
3
Cormorant Asset Management
Massachusetts
$922K – – –
BFM
4
Boothbay Fund Management
New York
$165K +$30.7K +3,559 +38%
KPWS
5
Kestra Private Wealth Services
Texas
$100K +$67.4K +7,810 New
Envestnet Asset Management
6
Envestnet Asset Management
Illinois
$41.2K +$2.47K +286 +10%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$37K – – –
ASN
8
Advisory Services Network
Georgia
$35.8K – – –
AWM
9
Activest Wealth Management
Florida
$24.3K – – –
Morgan Stanley
10
Morgan Stanley
New York
$21.1K +$863 +100 +6%
Osaic Holdings
11
Osaic Holdings
Arizona
$21K -$1.32K -153 -9%
UBS Group
12
UBS Group
Switzerland
$14.8K -$561 -65 -5%
NFSG
13
Newbridge Financial Services Group
Florida
$3.52K – – –
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$1K – – –
CS
15
Credit Suisse
Switzerland
$3 – – –
State Street
16
State Street
Massachusetts
– -$71K -7,160 Closed
Citadel Advisors
17
Citadel Advisors
Florida
– -$53K -5,307 Closed

CMMB Hedge Fund Activity: Q4 2022 in Review

14 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2022, worth a combined $10.6M — up 523% from $1.71M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CMMB and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.

The largest buyer was Ikarian Capital, adding an estimated $146K. The largest seller was State Street, exiting entirely with an estimated $71K sold.

  • 14 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2022, down from 15 in Q3 2022.
  • Funds reported $10.6M of Chemomab Therapeutics stock for Q4 2022, up 523% quarter-over-quarter.
  • 1 fund opened new Chemomab Therapeutics positions in Q4 2022 and 2 closed out, a net change of -1 holder.
  • The largest Chemomab Therapeutics buyer in Q4 2022 was Ikarian Capital, an estimated $146K added.
  • The largest Chemomab Therapeutics seller in Q4 2022 was State Street, an estimated $71K sold.

Based on aggregated 13F filings for Q4 2022.